Literature DB >> 33420946

SDHB large deletions are associated with absence of MIBG uptake in metastatic lesions of malignant paragangliomas.

Janaina Petenuci1, Gustavo F C Fagundes1, Anna Flavia F Benedetti1, Augusto G Guimaraes1, Ana Caroline F Afonso1, Flavia T Mota1, Aurea Luiza F Magalhães1, George B Coura-Filho2, Maria Claudia N Zerbini3, Sheila Siqueira3, Fabio L M Montenegro4, Victor Srougi5, Fabio Y Tanno5, Jose Luis Chambo5, Marcela S S Ferrari6,7, Joao Evangelista Bezerra Neto6,7, Maria Adelaide A Pereira8, Ana Claudia Latronico1, Maria Candida B V Fragoso1,9, Berenice B Mendonca1, Ana O Hoff7,9, Madson Q Almeida10,11.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33420946     DOI: 10.1007/s12020-020-02594-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  18 in total

1.  Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.

Authors:  Segolene Hescot; Maria Curras-Freixes; Timo Deutschbein; Anouk van Berkel; Delphine Vezzosi; Laurence Amar; Christelle de la Fouchardière; Nuria Valdes; Fernando Riccardi; Christine Do Cao; Jerome Bertherat; Bernard Goichot; Felix Beuschlein; Delphine Drui; Letizia Canu; Patricia Niccoli; Sandrine Laboureau; Antoine Tabarin; Sophie Leboulleux; Bruna Calsina; Rossella Libé; Antongiulio Faggiano; Martin Schlumberger; Francoise Borson-Chazot; Massimo Mannelli; Anne-Paule Gimenez-Roqueplo; Philippe Caron; Henri J L M Timmers; Martin Fassnacht; Mercedes Robledo; Isabelle Borget; Eric Baudin
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

2.  Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Marcella M Johnson; Shamim Ejaz; Mouhammed Amir Habra; Thereasa Rich; Naifa Busaidy; Gilbert J Cote; Nancy Perrier; Alexandria Phan; Shreyaskumar Patel; Steven Waguespack; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2010-12-29       Impact factor: 5.958

3.  Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.

Authors:  Lauren Fishbein; Ignaty Leshchiner; Vonn Walter; Ludmila Danilova; A Gordon Robertson; Amy R Johnson; Tara M Lichtenberg; Bradley A Murray; Hans K Ghayee; Tobias Else; Shiyun Ling; Stuart R Jefferys; Aguirre A de Cubas; Brandon Wenz; Esther Korpershoek; Antonio L Amelio; Liza Makowski; W Kimryn Rathmell; Anne-Paule Gimenez-Roqueplo; Thomas J Giordano; Sylvia L Asa; Arthur S Tischler; Karel Pacak; Katherine L Nathanson; Matthew D Wilkerson
Journal:  Cancer Cell       Date:  2017-02-02       Impact factor: 31.743

4.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop.

Authors:  Patricia L M Dahia; Roderick Clifton-Bligh; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo; Camilo Jimenez
Journal:  Endocr Relat Cancer       Date:  2020-08       Impact factor: 5.678

5.  Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.

Authors:  Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

6.  Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.

Authors:  Laurence Amar; Eric Baudin; Nelly Burnichon; Séverine Peyrard; Stéphane Silvera; Jérôme Bertherat; Xavier Bertagna; Martin Schlumberger; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo; Pierre-François Plouin
Journal:  J Clin Endocrinol Metab       Date:  2007-07-24       Impact factor: 5.958

Review 7.  Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma.

Authors:  Eric Baudin; Mouhammed Amir Habra; Frederic Deschamps; Gilbert Cote; Frederic Dumont; Maria Cabanillas; J Arfi-Roufe; A Berdelou; Bryan Moon; Abir Al Ghuzlan; Shreyaskumar Patel; Sophie Leboulleux; Camilo Jimenez
Journal:  Eur J Endocrinol       Date:  2014-06-02       Impact factor: 6.664

8.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

Authors:  Jacques W M Lenders; Quan-Yang Duh; Graeme Eisenhofer; Anne-Paule Gimenez-Roqueplo; Stefan K G Grebe; Mohammad Hassan Murad; Mitsuhide Naruse; Karel Pacak; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2014-06       Impact factor: 5.958

9.  Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.

Authors:  Henri J L M Timmers; Anna Kozupa; Clara C Chen; Jorge A Carrasquillo; Alexander Ling; Graeme Eisenhofer; Karen T Adams; Daniel Solis; Jacques W M Lenders; Karel Pacak
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

10.  Deletions of NF1 gene and exons detected by multiplex ligation-dependent probe amplification.

Authors:  A De Luca; I Bottillo; M C Dasdia; A Morella; V Lanari; L Bernardini; L Divona; S Giustini; L Sinibaldi; A Novelli; I Torrente; A Schirinzi; B Dallapiccola
Journal:  J Med Genet       Date:  2007-12       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.